Once-Weekly GLP-1 Drugs Compared: Semaglutide Leads in Blood Sugar and Weight Loss
Among once-weekly GLP-1 receptor agonists, semaglutide was superior to dulaglutide and exenatide for HbA1c reduction and weight loss, with all three offering cardiovascular and potential kidney benefits.
Quick Facts
What This Study Found
Semaglutide subcutaneous was superior to dulaglutide and exenatide ER for HbA1c and weight reduction in head-to-head trials, with both semaglutide and dulaglutide showing cardiovascular and renal benefits.
Key Numbers
31 trials; semaglutide superior to dulaglutide and exenatide ER for HbA1c and weight; CV benefits for semaglutide and dulaglutide
How They Did This
Narrative review of 31 Phase 3 clinical trials from dulaglutide, exenatide ER, and semaglutide clinical development programs, comparing glycemic, weight, cardiovascular, and renal outcomes.
Why This Research Matters
Clinicians need to choose between GLP-1 drugs for their patients. This comprehensive comparison helps match the right drug to the right patient based on glycemic, weight, and cardiovascular priorities.
The Bigger Picture
This review captures the moment when GLP-1 RAs transitioned from glucose-lowering drugs to multi-benefit therapies addressing diabetes, obesity, cardiovascular disease, and kidney protection simultaneously.
What This Study Doesn't Tell Us
Narrative review — not a formal meta-analysis; cross-trial comparisons have limitations; exenatide ER data less comprehensive than semaglutide; head-to-head vs. daily GLP-1 RAs had mixed results.
Questions This Raises
- ?Does semaglutide superiority justify its higher cost over dulaglutide?
- ?How do oral semaglutide results compare to the subcutaneous formulation?
- ?Will tirzepatide (dual GIP/GLP-1) outperform all single-target GLP-1 RAs?
Trust & Context
- Key Stat:
- Semaglutide superior head-to-head Superior to both dulaglutide and exenatide ER for HbA1c reduction and weight loss in direct comparison trials
- Evidence Grade:
- Based on 31 Phase 3 randomized trials including head-to-head comparisons and cardiovascular outcome trials — strong clinical evidence base.
- Study Age:
- Published in 2020; the GLP-1 landscape has since expanded with oral semaglutide, higher-dose semaglutide, and tirzepatide.
- Original Title:
- Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- Published In:
- Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 28-42 (2020)
- Authors:
- Patel, Dhiren
- Database ID:
- RPEP-05055
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which once-weekly GLP-1 drug is best for diabetes?
In head-to-head trials, semaglutide subcutaneous showed the strongest HbA1c reduction and weight loss, though all once-weekly GLP-1 drugs offer significant benefits beyond glucose control.
Are weekly GLP-1 shots better than insulin?
Once-weekly GLP-1 drugs matched insulin for blood sugar control while also promoting weight loss and avoiding hypoglycemia — two significant advantages over insulin therapy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05055APA
Patel, Dhiren. (2020). Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.. Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 28-42. https://doi.org/10.1111/jcpt.13224
MLA
Patel, Dhiren. "Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.." Journal of clinical pharmacy and therapeutics, 2020. https://doi.org/10.1111/jcpt.13224
RethinkPeptides
RethinkPeptides Research Database. "Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 re..." RPEP-05055. Retrieved from https://rethinkpeptides.com/research/patel-2020-glycaemic-and-nonglycaemic-efficacy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.